These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 12459415)

  • 1. Neuropsychiatric reaction induced by abacavir.
    Colebunders R; Hilbrands R; De Roo A; Pelgrom J
    Am J Med; 2002 Nov; 113(7):616. PubMed ID: 12459415
    [No Abstract]   [Full Text] [Related]  

  • 2. Neuropsychiatric reaction induced by abacavir in a pediatric human immunodeficiency virus-infected patient.
    Soler Palacin P; Aramburo A; Moraga FA; Cabañas MJ; Figueras C
    Pediatr Infect Dis J; 2006 Apr; 25(4):382. PubMed ID: 16568000
    [No Abstract]   [Full Text] [Related]  

  • 3. Sweet's syndrome following abacavir therapy.
    Del Giudice P; Vandenbos F; Perrin C; Bernard E; Marq L; Dellamonica P
    J Am Acad Dermatol; 2004 Sep; 51(3):474-5. PubMed ID: 15337997
    [No Abstract]   [Full Text] [Related]  

  • 4. Abacavir plus lamivudine: a thymidine analogue-sparing NRTI backbone.
    Moyle GJ
    AIDS Read; 2003 Nov; 13(11):528, 533-5. PubMed ID: 14649622
    [No Abstract]   [Full Text] [Related]  

  • 5. Summaries for patients. Neuropsychological side effects of efavirenz.
    Ann Intern Med; 2005 Nov; 143(10):I43. PubMed ID: 16287787
    [No Abstract]   [Full Text] [Related]  

  • 6. Lest we forget: neuropsychiatry and the new generation anti-HIV drugs.
    Gonzalez A; Everall IP
    AIDS; 1998 Dec; 12(18):2365-7. PubMed ID: 9875573
    [No Abstract]   [Full Text] [Related]  

  • 7. [Safety profile of rilpivirine: general and neuropsychiatric tolerability, safety in patients with hepatitis B or C viruses, and lipid profile].
    López Cortés LF; Martínez E; von Wichmann MÁ
    Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():6-11. PubMed ID: 24252528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial.
    Gutiérrez-Valencia A; Viciana P; Palacios R; Ruiz-Valderas R; Lozano F; Terrón A; Rivero A; López-Cortés LF;
    Ann Intern Med; 2009 Aug; 151(3):149-56. PubMed ID: 19581631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New variations in highly active antiretroviral therapy. Simple combination as a promising option].
    MMW Fortschr Med; 2000 Mar; 142 Suppl 1():50-2. PubMed ID: 10863312
    [No Abstract]   [Full Text] [Related]  

  • 10. Unusual clinical presentation of hypersensitivity reaction to abacavir.
    Aquilina C; Mularczyk M; Lucas F; Viraben R
    AIDS; 2003 Nov; 17(16):2403-4. PubMed ID: 14571198
    [No Abstract]   [Full Text] [Related]  

  • 11. Incidence of abacavir hypersensitivity reactions in euroSIDA.
    Bannister WP; Friis-Møller N; Mocroft A; Viard JP; van Lunzen J; Kirk O; Gargalianos P; Bánhegyi D; Chiesi A; Lundgren JD;
    Antivir Ther; 2008; 13(5):687-96. PubMed ID: 18771052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triple nuke therapy--results after one year.
    TreatmentUpdate; 2001; 12(10):3-4. PubMed ID: 11570063
    [No Abstract]   [Full Text] [Related]  

  • 13. The abacavir hypersensitivity reaction and interruptions in therapy.
    Loeliger AE; Steel H; McGuirk S; Powell WS; Hetherington SV
    AIDS; 2001 Jul; 15(10):1325-6. PubMed ID: 11426085
    [No Abstract]   [Full Text] [Related]  

  • 14. Acute respiratory manifestations of the abacavir hypersensitivity reaction.
    Herring SJ; Krieger AC
    AIDS; 2006 Jan; 20(2):301-2. PubMed ID: 16511430
    [No Abstract]   [Full Text] [Related]  

  • 15. Parsonage-Turner syndrome: a rare case of abacavir hypersensitivity reaction in HIV-infected patients.
    Bellagamba R; Tommasi C; De Marco M; Narciso P
    J Infect; 2008 Jul; 57(1):88-90. PubMed ID: 18514915
    [No Abstract]   [Full Text] [Related]  

  • 16. Preliminary report on 1592.
    AIDS Clin Care; 1997 Sep; 9(9):71. PubMed ID: 11364756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Agranulocytosis and fever seven weeks after starting abacavir.
    Sankatsing SU; Prins JM
    AIDS; 2001 Dec; 15(18):2464-5. PubMed ID: 11774836
    [No Abstract]   [Full Text] [Related]  

  • 18. 1592 (abacavir): do not rechallenge after hypersensitivity reaction.
    James JS
    AIDS Treat News; 1997 Dec; (No 285):1, 5. PubMed ID: 11364916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction.
    Martínez E; Larrousse M; Podzamczer D; Pérez I; Gutiérrez F; Loncá M; Barragán P; Deulofeu R; Casamitjana R; Mallolas J; Pich J; Gatell JM;
    AIDS; 2010 Jan; 24(3):F1-9. PubMed ID: 20009917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-HIV agents. Abacavir once or twice daily.
    TreatmentUpdate; 2005; 17(5):8. PubMed ID: 17219659
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.